Phase 1 Myeloma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• You have been diagnosed with multiple myeloma that has been treated with at least three different types of therapies, and your diagnosis has been confirmed through a tissue sample test.
• You fall into one of two risk groups: either you have "high-risk" myeloma (based on specific genetic features of your cancer, such as certain chromosome changes or gene mutations, or cancer that has spread outside the bone marrow), OR you have "standard-risk" myeloma where a sensitive test (called MRD testing) still detects cancer cells around 58–60 days after your CAR-T treatment.
• You have already received a specific CAR-T cell therapy called ciltacabtagene autoleucel (also known as cilta-cel or Carvykti) as part of your standard care.
• Your disease can be monitored using a specific blood/bone marrow test called ClonoSEQ MRD testing.
• You are at least 18 years old.
• You are generally able to carry out daily activities with no more than moderate limitations (confirm with trial site).
• Your bone marrow and organs (such as liver and kidneys) are functioning well enough to meet specific blood test thresholds set by the trial (confirm specific numbers with trial site).
• If you are a woman who could become pregnant, or a man, you must be willing and able to use reliable contraception during the study and for 90 days after finishing the study treatment.
• You are able to understand the study and are willing to sign a consent form (a legal representative may do this on your behalf if needed).

Who may not be able to join:

• Your multiple myeloma has spread to the brain or spinal fluid.
• Your myeloma has clearly gotten worse (progressed) after your CAR-T treatment, based on established medical criteria.
• You are still experiencing side effects from CAR-T therapy, such as a serious immune reaction (cytokine release syndrome) or neurological problems that have not resolved.
• You still have unresolved serious (grade 3 or higher) side effects from your CAR-T treatment that are not related to blood counts.
• You are receiving or planning to receive any other cancer treatment (such as chemotherapy, immunotherapy, or radiation) from 28 days after your CAR-T therapy until the end of the study (note: steroids taken for unrelated conditions may be allowed — confirm with trial site).
• You have already received a drug called selinexor, or a similar type of drug, after your CAR-T treatment.
• You have a serious medical or mental health condition that, in the doctor's opinion, could prevent you from completing the treatment.
• You have had an organ transplant in the past and are still taking medicines to prevent rejection.
• You have another cancer (past or current) that could interfere with assessing the safety or effectiveness of this trial's treatment (confirm with trial site).
• You are currently participating in another clinical trial involving an experimental treatment.
• You have had a serious allergic reaction to selinexor or to drugs with a similar chemical makeup.
• You have a stomach or digestive condition that makes it difficult to swallow tablets or that would stop your body from absorbing the study medicine properly.
• You have an uncontrolled ongoing illness, such as a serious active infection requiring IV antibiotics, antiviral, or antifungal medicines in the week before starting treatment, or significant unstable heart problems (confirm specific heart conditions with trial site).
• You have had major surgery within 28 days before starting the study treatment.
• You are pregnant or breastfeeding, or are a woman of childbearing potential and cannot provide a negative pregnancy test within 7 days of starting treatment.
• You have HIV and are not on effective treatment with an undetectable viral load for at least 6 months (those with HIV who are well-controlled on treatment may be eligible).
• You have chronic hepatitis B virus (HBV) that is detectable, even if you are on treatment (those with undetectable levels on suppressive therapy may be eligible).
• You have a history of hepatitis C virus (HCV) infection that has not been fully treated and cured, or where the virus is still detectable (those who are cured or have undetectable levels on active treatment may be eligible).

Important: Always verify eligibility with the trial site directly before applying.